Last updated on April 2019

A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Brief description of study

Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of VT-1161 suggest that it might be a safer and more effective treatment for RVVC than other oral antifungal medicines.

This study will evaluate the effectiveness and safety of VT-1161 for the treatment of RVVC and consists of 2 parts. The first part of the study is a 2-week period for the treatment of the patient's current VVC episode with 3 150mg doses of fluconazole. The 2nd part consists of 12 weeks, when the patient will take either VT-1161 150 mg or a placebo (according to a random assignment), and then a 36-week follow-up period.

This study is identical to VMT-VT-1161-CL-011.

Clinical Study Identifier: NCT03561701

Find a site near you

Start Over

Jackson Clinic North

Jackson, TN United States
  Connect »

Bravo Health Care Center

North Bay Village, FL United States
  Connect »

HWC Women's Research Center

Englewood, OH United States
  Connect »

Clinical Trials of America

Winston-Salem, NC United States
  Connect »

Matrix Clinical Research

Los Angeles, CA United States
  Connect »

Precision Trials

Phoenix, AZ United States
  Connect »

Vida Clinical Trials

Homestead, FL United States
  Connect »